Cargando…
A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway networks. Systems biology approaches afford bett...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444693/ https://www.ncbi.nlm.nih.gov/pubmed/27302920 http://dx.doi.org/10.18632/oncotarget.8747 |
_version_ | 1783238744452628480 |
---|---|
author | Bown, James L. Shovman, Mark Robertson, Paul Boiko, Andrei Goltsov, Alexey Mullen, Peter Harrison, David J. |
author_facet | Bown, James L. Shovman, Mark Robertson, Paul Boiko, Andrei Goltsov, Alexey Mullen, Peter Harrison, David J. |
author_sort | Bown, James L. |
collection | PubMed |
description | Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway networks. Systems biology approaches afford better understanding of complex, dynamical interactions in signalling pathways targeted by anticancer drugs. However, adoption of dynamical modelling by clinicians and biologists is impeded by model inaccessibility. Drawing on computer games technology, we present a novel visualization toolkit, SiViT, that converts systems biology models of cancer cell signalling into interactive simulations that can be used without specialist computational expertise. SiViT allows clinicians and biologists to directly introduce for example loss of function mutations and specific inhibitors. SiViT animates the effects of these introductions on pathway dynamics, suggesting further experiments and assessing candidate biomarker effectiveness. In a systems biology model of Her2 signalling we experimentally validated predictions using SiViT, revealing the dynamics of biomarkers of drug resistance and highlighting the role of pathway crosstalk. No model is ever complete: the iteration of real data and simulation facilitates continued evolution of more accurate, useful models. SiViT will make accessible libraries of models to support preclinical research, combinatorial strategy design and biomarker discovery. |
format | Online Article Text |
id | pubmed-5444693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54446932017-06-01 A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT Bown, James L. Shovman, Mark Robertson, Paul Boiko, Andrei Goltsov, Alexey Mullen, Peter Harrison, David J. Oncotarget Research Paper Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway networks. Systems biology approaches afford better understanding of complex, dynamical interactions in signalling pathways targeted by anticancer drugs. However, adoption of dynamical modelling by clinicians and biologists is impeded by model inaccessibility. Drawing on computer games technology, we present a novel visualization toolkit, SiViT, that converts systems biology models of cancer cell signalling into interactive simulations that can be used without specialist computational expertise. SiViT allows clinicians and biologists to directly introduce for example loss of function mutations and specific inhibitors. SiViT animates the effects of these introductions on pathway dynamics, suggesting further experiments and assessing candidate biomarker effectiveness. In a systems biology model of Her2 signalling we experimentally validated predictions using SiViT, revealing the dynamics of biomarkers of drug resistance and highlighting the role of pathway crosstalk. No model is ever complete: the iteration of real data and simulation facilitates continued evolution of more accurate, useful models. SiViT will make accessible libraries of models to support preclinical research, combinatorial strategy design and biomarker discovery. Impact Journals LLC 2016-05-18 /pmc/articles/PMC5444693/ /pubmed/27302920 http://dx.doi.org/10.18632/oncotarget.8747 Text en Copyright: © 2017 Bown et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Bown, James L. Shovman, Mark Robertson, Paul Boiko, Andrei Goltsov, Alexey Mullen, Peter Harrison, David J. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT |
title | A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT |
title_full | A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT |
title_fullStr | A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT |
title_full_unstemmed | A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT |
title_short | A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT |
title_sort | signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: sivit |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444693/ https://www.ncbi.nlm.nih.gov/pubmed/27302920 http://dx.doi.org/10.18632/oncotarget.8747 |
work_keys_str_mv | AT bownjamesl asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT shovmanmark asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT robertsonpaul asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT boikoandrei asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT goltsovalexey asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT mullenpeter asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT harrisondavidj asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT bownjamesl signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT shovmanmark signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT robertsonpaul signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT boikoandrei signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT goltsovalexey signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT mullenpeter signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit AT harrisondavidj signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit |